MARKET

CGEN

CGEN

Compugen
NASDAQ
1.880
-0.080
-4.08%
After Hours: 1.880 0 0.00% 19:30 11/19 EST
OPEN
1.970
PREV CLOSE
1.960
HIGH
1.995
LOW
1.840
VOLUME
262.64K
TURNOVER
--
52 WEEK HIGH
3.235
52 WEEK LOW
1.430
MARKET CAP
178.09M
P/E (TTM)
4.993
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CGEN last week (1109-1113)?
Weekly Report · 3d ago
Compugen Earnings Call Highlights Clinical Progress and Cash Runway
TipRanks · 5d ago
Compugen: Buy Reiterated as Clinical Catalysts and Partner Programs Support Unchanged $4 Price Target
TipRanks · 11/12 11:56
Compugen: COM701 Data On Track And Continued Bispecific Rilvegostomig Development
Seeking Alpha · 11/10 16:49
Oppenheimer Reaffirms Their Buy Rating on Compugen (CGEN)
TipRanks · 11/10 12:56
Stifel Nicolaus Remains a Buy on Compugen (CGEN)
TipRanks · 11/10 12:27
Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
PR Newswire · 11/10 12:00
Compugen (CGEN) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/09 17:13
More
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Webull offers Compugen Ltd (USA) stock information, including NASDAQ: CGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEN stock methods without spending real money on the virtual paper trading platform.